Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells $880,000.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $110.00, for a total value of $880,000.00. Following the completion of the sale, the insider directly owned 208,000 shares of the company’s stock, valued at approximately $22,880,000. This represents a 3.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Trading Up 5.3%

Shares of BLLN traded up $5.93 during mid-day trading on Friday, reaching $118.17. The company’s stock had a trading volume of 962,346 shares, compared to its average volume of 476,253. The stock has a market cap of $5.44 billion and a PE ratio of 214.85. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70. The company’s fifty day moving average price is $91.82 and its two-hundred day moving average price is $87.11.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. Billiontoone’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.39) EPS. On average, analysts predict that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Institutional Trading of Billiontoone

Institutional investors have recently modified their holdings of the company. Adams Street Partners LLC purchased a new position in Billiontoone during the 4th quarter valued at about $140,063,000. Baillie Gifford & Co. bought a new stake in shares of Billiontoone in the 4th quarter worth approximately $103,786,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Billiontoone during the fourth quarter valued at approximately $39,717,000. JPMorgan Chase & Co. bought a new position in shares of Billiontoone during the fourth quarter valued at approximately $32,078,000. Finally, Wasatch Advisors LP bought a new position in shares of Billiontoone during the first quarter valued at approximately $29,179,000.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Guggenheim lifted their price objective on Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. Wells Fargo & Company decreased their price target on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. JPMorgan Chase & Co. increased their price objective on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.